ATE402710T1 - Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen - Google Patents
Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungenInfo
- Publication number
- ATE402710T1 ATE402710T1 AT04702722T AT04702722T ATE402710T1 AT E402710 T1 ATE402710 T1 AT E402710T1 AT 04702722 T AT04702722 T AT 04702722T AT 04702722 T AT04702722 T AT 04702722T AT E402710 T1 ATE402710 T1 AT E402710T1
- Authority
- AT
- Austria
- Prior art keywords
- alpha
- pregnenolone
- methoxy
- production
- treatment
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 229960000249 pregnenolone Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 230000001154 acute effect Effects 0.000 abstract 2
- 230000003902 lesion Effects 0.000 abstract 2
- 210000000653 nervous system Anatomy 0.000 abstract 2
- OGNJZVNNKBZFRM-UHFFFAOYSA-N 1-(5-methoxy-1H-indol-3-yl)-2-propanamine Chemical compound COC1=CC=C2NC=C(CC(C)N)C2=C1 OGNJZVNNKBZFRM-UHFFFAOYSA-N 0.000 abstract 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 150000002118 epoxides Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003132 pregnenolones Chemical class 0.000 abstract 1
- -1 steroid compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0300507A FR2850023B1 (fr) | 2003-01-17 | 2003-01-17 | Medicaments pour le systeme nerveux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402710T1 true ATE402710T1 (de) | 2008-08-15 |
Family
ID=32605831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04702722T ATE402710T1 (de) | 2003-01-17 | 2004-01-16 | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8034798B2 (de) |
| EP (1) | EP1583538B1 (de) |
| AT (1) | ATE402710T1 (de) |
| DE (1) | DE602004015406D1 (de) |
| DK (1) | DK1583538T3 (de) |
| ES (1) | ES2311790T3 (de) |
| FR (1) | FR2850023B1 (de) |
| PT (1) | PT1583538E (de) |
| WO (1) | WO2004067010A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| WO2008109719A2 (en) * | 2007-03-07 | 2008-09-12 | Janssen Pharmaceutica N.V. | Steroids derivatives as selective progesterone receptor modulators |
| PL2709631T3 (pl) * | 2011-05-20 | 2017-07-31 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Antagoniści receptora cb1 |
| CA2848212C (en) * | 2011-09-08 | 2022-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2621528T3 (es) * | 2012-11-28 | 2017-07-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Derivados de 3-(4-sustituido)-bencil éter de pregnenolona |
| PT2968369T (pt) | 2013-03-13 | 2018-12-05 | Sage Therapeutics Inc | Esteroides neuroativos e métodos para o seu uso |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2991311C (en) | 2015-07-06 | 2025-05-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND THEIR METHODS OF USE |
| HUE071964T2 (hu) | 2015-07-06 | 2025-10-28 | Sage Therapeutics Inc | Oxiszterolok és alkalmazási eljárásaik |
| EP3828194B1 (de) | 2015-07-06 | 2025-04-16 | Sage Therapeutics, Inc. | Oxysterole und verfahren zur verwendung davon |
| EP3165225A1 (de) | 2015-11-06 | 2017-05-10 | Mapreg | Nicht biologisch umsetzbare c3-substitutierte pregnenolonderivate zur behandlung von drogenmissbrauch |
| EP3436024B1 (de) | 2016-03-01 | 2026-04-08 | Mapreg | 3-beta-methoxy-preg zur verwendung bei der behandlung von behandlungsresistenten depressionen |
| US9943528B2 (en) | 2016-03-01 | 2018-04-17 | Mapreg | Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression |
| SMT202200300T1 (it) | 2016-04-01 | 2022-09-14 | Sage Therapeutics Inc | Ossisteroli e relativi metodi d'uso |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| KR20230051723A (ko) | 2016-10-18 | 2023-04-18 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563131A (en) * | 1994-08-04 | 1996-10-08 | Pherin Corporation | Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods |
| EP0840612A1 (de) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate |
| US6245757B1 (en) * | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| FR2806303B1 (fr) * | 2000-03-17 | 2002-09-27 | Inst Nat Sante Rech Med | Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| AU2002217841A1 (en) * | 2000-11-06 | 2002-05-15 | Trustees Of Boston University | Neuroactive steroid derivatives and methods of use |
| EP1310258A1 (de) * | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Steroid-Enantiomere zur Erhöhung des Erinnerungsvermögens und der kognitiven Funktion |
| US9339508B2 (en) * | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
-
2003
- 2003-01-17 FR FR0300507A patent/FR2850023B1/fr not_active Expired - Lifetime
-
2004
- 2004-01-16 PT PT04702722T patent/PT1583538E/pt unknown
- 2004-01-16 EP EP04702722A patent/EP1583538B1/de not_active Expired - Lifetime
- 2004-01-16 DK DK04702722T patent/DK1583538T3/da active
- 2004-01-16 US US10/542,495 patent/US8034798B2/en not_active Expired - Lifetime
- 2004-01-16 WO PCT/FR2004/000086 patent/WO2004067010A1/fr not_active Ceased
- 2004-01-16 ES ES04702722T patent/ES2311790T3/es not_active Expired - Lifetime
- 2004-01-16 DE DE602004015406T patent/DE602004015406D1/de not_active Expired - Lifetime
- 2004-01-16 AT AT04702722T patent/ATE402710T1/de active
-
2008
- 2008-09-26 US US12/232,993 patent/US8334278B2/en not_active Expired - Lifetime
-
2015
- 2015-11-24 US US14/950,178 patent/US10561671B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2850023B1 (fr) | 2007-04-06 |
| US10561671B2 (en) | 2020-02-18 |
| DK1583538T3 (da) | 2008-12-01 |
| EP1583538B1 (de) | 2008-07-30 |
| US20090143347A1 (en) | 2009-06-04 |
| PT1583538E (pt) | 2008-10-30 |
| US20060199790A1 (en) | 2006-09-07 |
| US20160166586A1 (en) | 2016-06-16 |
| US8334278B2 (en) | 2012-12-18 |
| US8034798B2 (en) | 2011-10-11 |
| ES2311790T3 (es) | 2009-02-16 |
| DE602004015406D1 (de) | 2008-09-11 |
| EP1583538A1 (de) | 2005-10-12 |
| WO2004067010A1 (fr) | 2004-08-12 |
| FR2850023A1 (fr) | 2004-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE402710T1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
| ATE268179T1 (de) | Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| AU2003298094A1 (en) | Medicinal arylethanolamine compounds | |
| NO20070576L (no) | Nye hydantionderivater for behandling av obstruktive luftveissykdommer. | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| SE0104340D0 (sv) | New compounds | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| ATE381537T1 (de) | Formanilid-derivative als beta2-adrenorezeptor- agonisten | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE602005023782D1 (de) | Pyrrolidinderivate zur behandlung einer von der reninaktivität abhängigen krankheit | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ATE340579T1 (de) | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung | |
| AR040441A1 (es) | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento | |
| ATE453617T1 (de) | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien | |
| EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
| ATE308537T1 (de) | Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE50006842D1 (de) | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung | |
| DE60041137D1 (de) | Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| ATE492285T1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1583538 Country of ref document: EP |